Different dissolution conditions affect stability and dissolution profiles of bioequivalent levodopa-containing oral dosage forms.

Johanna Weitzel; Angelika Wünsch; Olaf Rose; Klaus Langer

doi:10.1016/j.ijpharm.2022.122401

Different dissolution conditions affect stability and dissolution profiles of bioequivalent levodopa-containing oral dosage forms.

Johanna Weitzel, Angelika Wünsch, Olaf Rose (Co-author), Klaus Langer

Research output: Contribution to journal › Original Article › peer-review

2 Citations (Web of Science)

Original language	English
Pages (from-to)	122401
Journal	INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume	629
DOIs	https://doi.org/10.1016/j.ijpharm.2022.122401
Publication status	Published - 2022

Keywords

PARKINSONS-DISEASE
PERFORMANCE
DEGRADATION
CARBIDOPA
MELANIN

Access to Document

10.1016/j.ijpharm.2022.122401

Cite this

@article{7b02efa8ef28434fb292fa9adcea77ee,

title = "Different dissolution conditions affect stability and dissolution profiles of bioequivalent levodopa-containing oral dosage forms.",

keywords = "PARKINSONS-DISEASE, PERFORMANCE, DEGRADATION, CARBIDOPA, MELANIN",

author = "Johanna Weitzel and Angelika W{\"u}nsch and Olaf Rose and Klaus Langer",

note = "Rose: impac2t research, Maximilianstr, 31-33, 48147 Muenster, Germany; Department of Pharmacotherapy \& Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.",

year = "2022",

doi = "10.1016/j.ijpharm.2022.122401",

language = "English",

volume = "629",

pages = "122401",

journal = "INTERNATIONAL JOURNAL OF PHARMACEUTICS",

issn = "0378-5173",

}

TY - JOUR

T1 - Different dissolution conditions affect stability and dissolution profiles of bioequivalent levodopa-containing oral dosage forms.

AU - Weitzel, Johanna

AU - Wünsch, Angelika

AU - Rose, Olaf

AU - Langer, Klaus

N1 - Rose: impac2t research, Maximilianstr, 31-33, 48147 Muenster, Germany; Department of Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.

PY - 2022

Y1 - 2022

KW - PARKINSONS-DISEASE

KW - PERFORMANCE

KW - DEGRADATION

KW - CARBIDOPA

KW - MELANIN

U2 - 10.1016/j.ijpharm.2022.122401

DO - 10.1016/j.ijpharm.2022.122401

M3 - Original Article

C2 - 36395922

SN - 0378-5173

VL - 629

SP - 122401

JO - INTERNATIONAL JOURNAL OF PHARMACEUTICS

JF - INTERNATIONAL JOURNAL OF PHARMACEUTICS

ER -